CR20150005A - Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo [4,3-b] piridazin-3-il] sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea - Google Patents
Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo [4,3-b] piridazin-3-il] sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureaInfo
- Publication number
- CR20150005A CR20150005A CR20150005A CR20150005A CR20150005A CR 20150005 A CR20150005 A CR 20150005A CR 20150005 A CR20150005 A CR 20150005A CR 20150005 A CR20150005 A CR 20150005A CR 20150005 A CR20150005 A CR 20150005A
- Authority
- CR
- Costa Rica
- Prior art keywords
- triazolo
- urea
- iletil
- fluorophenil
- piridazin
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 1
- ODIUNTQOXRXOIV-UHFFFAOYSA-N 1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(F)=CC=C1C1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 ODIUNTQOXRXOIV-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305840 | 2012-07-12 | ||
| PCT/EP2013/064741 WO2014009500A1 (en) | 2012-07-12 | 2013-07-11 | Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150005A true CR20150005A (es) | 2015-04-06 |
Family
ID=48782350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150005A CR20150005A (es) | 2012-07-12 | 2015-01-07 | Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo [4,3-b] piridazin-3-il] sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150119391A1 (enExample) |
| EP (1) | EP2872119A1 (enExample) |
| JP (1) | JP2015525754A (enExample) |
| KR (1) | KR20150030761A (enExample) |
| CN (1) | CN104470500A (enExample) |
| AR (1) | AR091727A1 (enExample) |
| AU (1) | AU2013288676A1 (enExample) |
| BR (1) | BR112015000497A2 (enExample) |
| CA (1) | CA2878500A1 (enExample) |
| CL (1) | CL2015000074A1 (enExample) |
| CO (1) | CO7160069A2 (enExample) |
| CR (1) | CR20150005A (enExample) |
| EA (1) | EA201590199A1 (enExample) |
| HK (1) | HK1209642A1 (enExample) |
| IL (1) | IL236662A0 (enExample) |
| IN (1) | IN2015KN00075A (enExample) |
| MA (1) | MA37753B1 (enExample) |
| MX (1) | MX2015000532A (enExample) |
| PH (1) | PH12015500060A1 (enExample) |
| SG (1) | SG11201500123XA (enExample) |
| TN (1) | TN2015000011A1 (enExample) |
| TW (1) | TW201402121A (enExample) |
| UY (1) | UY34909A (enExample) |
| WO (1) | WO2014009500A1 (enExample) |
| ZA (1) | ZA201500129B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022414970A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
| CN1774259B (zh) * | 2003-01-14 | 2011-12-28 | 特瓦制药工业有限公司 | 治疗系统性红斑狼疮的肽的胃肠道外制剂 |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| EP2252291A1 (en) * | 2008-02-28 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| CN101444510B (zh) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
-
2013
- 2013-07-11 EP EP13735312.4A patent/EP2872119A1/en not_active Withdrawn
- 2013-07-11 SG SG11201500123XA patent/SG11201500123XA/en unknown
- 2013-07-11 EA EA201590199A patent/EA201590199A1/ru unknown
- 2013-07-11 BR BR112015000497A patent/BR112015000497A2/pt not_active IP Right Cessation
- 2013-07-11 MX MX2015000532A patent/MX2015000532A/es unknown
- 2013-07-11 CA CA 2878500 patent/CA2878500A1/en not_active Abandoned
- 2013-07-11 IN IN75KON2015 patent/IN2015KN00075A/en unknown
- 2013-07-11 TW TW102124952A patent/TW201402121A/zh unknown
- 2013-07-11 KR KR20157003404A patent/KR20150030761A/ko not_active Withdrawn
- 2013-07-11 WO PCT/EP2013/064741 patent/WO2014009500A1/en not_active Ceased
- 2013-07-11 CN CN201380037070.8A patent/CN104470500A/zh active Pending
- 2013-07-11 AU AU2013288676A patent/AU2013288676A1/en not_active Abandoned
- 2013-07-11 HK HK15110497.0A patent/HK1209642A1/xx unknown
- 2013-07-11 MA MA37753A patent/MA37753B1/fr unknown
- 2013-07-11 AR ARP130102458 patent/AR091727A1/es unknown
- 2013-07-11 JP JP2015521001A patent/JP2015525754A/ja active Pending
- 2013-07-12 UY UY34909A patent/UY34909A/es not_active Application Discontinuation
-
2015
- 2015-01-07 CR CR20150005A patent/CR20150005A/es unknown
- 2015-01-08 TN TNP2015000011A patent/TN2015000011A1/fr unknown
- 2015-01-08 ZA ZA2015/00129A patent/ZA201500129B/en unknown
- 2015-01-08 CO CO15004112A patent/CO7160069A2/es unknown
- 2015-01-09 CL CL2015000074A patent/CL2015000074A1/es unknown
- 2015-01-09 PH PH12015500060A patent/PH12015500060A1/en unknown
- 2015-01-09 US US14/593,059 patent/US20150119391A1/en not_active Abandoned
- 2015-01-11 IL IL236662A patent/IL236662A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150030761A (ko) | 2015-03-20 |
| HK1209642A1 (en) | 2016-04-08 |
| US20150119391A1 (en) | 2015-04-30 |
| EP2872119A1 (en) | 2015-05-20 |
| MA37753A2 (fr) | 2016-06-30 |
| CO7160069A2 (es) | 2015-01-15 |
| CN104470500A (zh) | 2015-03-25 |
| UY34909A (es) | 2013-11-29 |
| MA37753B1 (fr) | 2019-04-30 |
| IN2015KN00075A (enExample) | 2015-07-31 |
| AU2013288676A1 (en) | 2015-02-05 |
| MA37753A3 (fr) | 2018-05-31 |
| TW201402121A (zh) | 2014-01-16 |
| TN2015000011A1 (en) | 2016-06-29 |
| IL236662A0 (en) | 2015-02-26 |
| WO2014009500A1 (en) | 2014-01-16 |
| CL2015000074A1 (es) | 2015-06-12 |
| BR112015000497A2 (pt) | 2017-06-27 |
| PH12015500060A1 (en) | 2015-03-02 |
| CA2878500A1 (en) | 2014-01-16 |
| ZA201500129B (en) | 2015-12-23 |
| JP2015525754A (ja) | 2015-09-07 |
| MX2015000532A (es) | 2015-05-15 |
| AR091727A1 (es) | 2015-02-25 |
| EA201590199A1 (ru) | 2015-05-29 |
| SG11201500123XA (en) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
| MX2015009209A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| CL2013002005A1 (es) | Compuesto 8-[5-(1-hidroxi-1-metiletil)piridin-3-il]-1-[(2s)-2-metoxipropil]-3-metil-1,3-dihidro-2h-imidazo[4,5-c]quinazolin-2-ona; inhibidor pi3k y como mtor; composicion farmaceutica que lo comprende; combinacion farmceutica; y su uso en el tratamiento del cancer. | |
| ECSP12011943A (es) | Antagonistas de espiro-oxindol de mdm2 | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| MX367897B (es) | Derivados de piridazinona macrociclicos. | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| CL2016000150A1 (es) | Compuestos y composiciones como inhibidores de la mek | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| MY191628A (en) | Novel triazolo[4,5-d]pyrimidine derivatives | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| CY1116186T1 (el) | Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους | |
| DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CR20150005A (es) | Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo [4,3-b] piridazin-3-il] sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea | |
| MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
| CO7151515A2 (es) | Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina | |
| NZ601661A (en) | Compositions and methods for treating viral diseases | |
| PE20142020A1 (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
| CL2008001216A1 (es) | Compuestos derivados de pirazol-3-il-amino-pirimidina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. |